Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma - Moskowitz, AJ; Shah, G; Schöder, H (JCO, 2021)
et al.